關鍵數據
1.210今開
1.230最高
59.85K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.06%換手率
1.180昨收
1.190最低
72.25K成交額
虧損本益比靜
0.80市淨率
0.00%股息率 TTM
-18.43%ROA
1.86552週最高
67.77量比
-41.05M淨利潤
106.13M總股本
-0.3669每股盈餘TTM
1.21Beta
-21.30%ROE
0.64352週最低
3.39%振幅
69.19%毛利率
126.83M總市值
3.05回報/風險
4.37%風險率

即將為您帶來更多新聞,敬請期待。 。 。
MaxCyte Inc評分
0.07與上次評分對比預測8.67
財務診斷6.36
技術分析4.36
公司估值7.96
機構認同度7.00
風險評估2.80
分析師評級
買入評級
4.107目標均價
+245.17%漲幅空間
MaxCyte Inc 最新財報電話會記錄
MaxCyte (MXCT) 2026 年第二季法說會:隨著與基因泰克合作擴大,重申財測指引
MaxCyte 2026 年第二季營收下降 15% 至 730 萬美元,同時成本下降,並維持 2026 年財測指引。基因泰克與 DTx 為下半年成長提供支撐。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
MaxCyte Inc 簡介
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
行業醫療設備與耗材
公司代碼MXCT
員工數量114
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| Capricorn Fund Managers Ltd | 7.65% |
|---|
| BlackRock Institutional Trust Company, N.A. | 6.96% |
|---|
| River Global Investors LLP | 5.13% |
|---|
| Vitruvian Partners LLP | 4.71% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 28.60% |
|---|
| Investment Advisor/Hedge Fund | 20.75% |
|---|
| Hedge Fund | 8.15% |
|---|
| Private Equity | 4.71% |
|---|
常見問題
MaxCyte Inc(MXCT)的當前股價是多少?
MaxCyte Inc(MXCT)的當前股價是 1.20。
MaxCyte Inc股票的52週最高點是多少?
MaxCyte Inc股票的52週最高點是1.86。
MaxCyte Inc股票的52週最低點是多少?
MaxCyte Inc股票的52週最低點是0.64。
現在MaxCyte Inc(MXCT)的股票是買入、持有還是賣出?
根據分析師評級,MaxCyte Inc(MXCT)的總體評級為買入,目標價格為4.11。
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.37。